These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 1879046)
1. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma. Guaitani A; Corada M; Lucas C; Lemoine A; Garattini S; Bartosek I Cancer Chemother Pharmacol; 1991; 28(4):293-7. PubMed ID: 1879046 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection. Bartosek I; Corada M; Dallarda S; Lucas C; Deloffre P; Guaitani A Xenobiotica; 1991 Feb; 21(2):235-42. PubMed ID: 2058178 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of nitrosoureas: levels of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in organs of normal and Walker 256/B carcinoma bearing rats after i.v. bolus. Bartosek I; Russo RG; Cattaneo MT Tumori; 1984 Dec; 70(6):491-8. PubMed ID: 6531791 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036. Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116 [TBL] [Abstract][Full Text] [Related]
5. Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies. Meulemans A; Giroux B; Hannoun P; Robine D; Henzel D Chemotherapy; 1991; 37(2):86-92. PubMed ID: 2032474 [TBL] [Abstract][Full Text] [Related]
6. Permeability of two nitrosoureas, carmustine and fotemustine in rat cortex. Meulemans A; Giroux B; Hannoun P; Henzel D; Bizzari JP; Mohler J Chemotherapy; 1989; 35(5):313-9. PubMed ID: 2791708 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Filippeschi S; Colombo T; Bassani D; De Francesco L; Arioli P; D'Incalci M; Bartosek I; Guaitani A Anticancer Res; 1988; 8(6):1351-4. PubMed ID: 3064716 [TBL] [Abstract][Full Text] [Related]
8. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692 [TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor growth inhibitory and toxic effects of a new fluorouracil--nitrosourea derivative (B-3839). Prajda N; Kralovánszky J; Somfai-Relle S; Gál F; Kerpel-Fronius S In Vivo; 1988; 2(2):151-4. PubMed ID: 2979832 [TBL] [Abstract][Full Text] [Related]
12. Focus on Fotemustine. De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834 [TBL] [Abstract][Full Text] [Related]
13. Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat. Fiebig HH; Eisenbrand G; Zeller WJ; Zentgraf R Oncology; 1980; 37(3):177-83. PubMed ID: 6444708 [TBL] [Abstract][Full Text] [Related]
14. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), and on the plasma pharmacokinetics and biotransformation of BCNU. Levin VA; Stearns J; Byrd A; Finn A; Weinkam RJ J Pharmacol Exp Ther; 1979 Jan; 208(1):1-6. PubMed ID: 759602 [TBL] [Abstract][Full Text] [Related]
15. In vivo chemosensitization by misonidazole in sensitive and resistant tumor lines. Mulcahy RT; Siemann DW Cancer Res; 1983 Oct; 43(10):4709-13. PubMed ID: 6883329 [TBL] [Abstract][Full Text] [Related]
16. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793 [TBL] [Abstract][Full Text] [Related]
17. O6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. D'Incalci M; Taverna P; Erba E; Filippeschi S; Potenza D; Mariani L; Citti L; Catapano CV Anticancer Res; 1991; 11(1):115-21. PubMed ID: 2018345 [TBL] [Abstract][Full Text] [Related]
18. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations. Wong KH; Wallen CA; Wheeler KT Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824 [TBL] [Abstract][Full Text] [Related]
19. Chemical and glutathione conjugation-related degradation of fotemustine: formation and characterization of a glutathione conjugate of diethyl (1-isocyanatoethyl)phosphonate, a reactive metabolite of fotemustine. Brakenhoff JP; Commandeur JN; de Kanter FJ; van Baar BL; Luijten WC; Vermeulen NP Chem Res Toxicol; 1994; 7(3):380-9. PubMed ID: 8075370 [TBL] [Abstract][Full Text] [Related]
20. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications]. Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]